Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06743737
Recruiting Observational

Digital Device Reading Skin Prick Test

NCT06743737 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Started
2024-11-01
Last updated
2024-12-20

Condition(s) studied

Allergy Skin Prick Test Reading

Investigational drug(s) / intervention(s)

Digital skin test reading device

Digital skin test reading device: The device to be studied measures optically the size of the wheals from skin tests (SPT) performed for the diagnosis of allergen sensitization.

Study summary

Skin prick tests (SPTs), or intraepidermal tests, are the first diagnostic approach for people with a suspected allergy. SPTs are very simple, safe and quick. They are cheap tests and are very useful as a screening test for allergy, especially in diseases like bronchial asthma, rhinoconjunctivitis, food/drug allergy and anaphylaxis. Together with the clinical history, SPTs allow to draw conclusions on allergies based on the sensitization pattern.

Nevertheless, the technique itself has evolved very little and continues to be performed entirely manually. This has a few drawbacks that limit the utility of the tests, in many cases limiting them to a purely qualitative assessment.

In comparison to standard practice (manual measurement), the digital skin test reading device Nexkin DSPT can provide the following benefits for project participants: Automates and digitizes the test reading, provides test results in digital format, reduces variability and subjectivity and greater consistency of diagnosis, reduces manual tasks allowing health professionals providing quantitative instead of qualitative results and avoiding potential human errors and allows a faster workflow, resulting in shorter patient visits.

The aim of this study is to validate the clinical utility of the electromedical skin test reading device Nexkin DSPT regarding its use in allergology clinics for the reading of skin prick allergy tests. The overall purpose of the study is to determine the sensitivity and specificity of skin prick tests (SPT) performed using the current practice of the fully manual SPT procedure and those performed using the Nexkin SPT DSPT (digital) procedure and to compare the sensitivity and specificity of both methods.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Patients who will undergo skin prick tests with panels of aeroallergens and/or foods. Over 18 years of age. The patient or their representative has given consent to participate in the study. The patient must not have taken an antihistamine in the last 5 days. Exclusion Criteria: Patients who are evaluated by more than 40 prick tests. Patients who have taken an antihistamine within the previous 5 days. Patients who are being treated with antidepressants or other drugs with an antihistamine effect. Patients who suffer severe atopic dermatitis with forearm involvement. Patients with dermographism. Patients who are evaluated by intradermal testing. Pregnant women or women suspected to be pregnant. Vulnerable patients

Primary outcome measure(s)

  • Measurement of the histamine (positive control) wheal by healthcare professional — At enrollment
  • Measurement of the NaCl (negative control) wheal by healthcare professional — At enrollment
  • Measurement of the histamine (positive control) wheal by digital device — At enrollment
  • Measurement of the NaCl (negative control) wheal by digital device — At enrollment

Trial sites (1)

FacilityCityRegionStatus
Inselspital, Bern University Hospital, University of Bern Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) Starting soon
Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT Recruiting
Neck Rescue Access Comparison Enrolling by invitation
Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine Recruiting
Surrogating Physician-recorded SCORE2 Risk Calculator Inputs by Using Auxiliary Data Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06743737 on ClinicalTrials.gov ↗ ← All trials in Switzerland